[CAS NO. 342639-96-7]  KRIBB11

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [342639-96-7]

Catalog
SLK-S8402
Brand
Selleck
CAS
342639-96-7

DESCRIPTION [342639-96-7]

Overview

MDLMFCD30182306
Molecular Weight284.27
Molecular FormulaC13H12N6O2
SMILESO=[N+](C1=CC=C(NC)N=C1NC2=CC3=C(NN=C3)C=C2)[O-]

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

1 mg5 mg10 mg
1 mM3.5178 mL17.5889 mL35.1778 mL
5 mM0.7036 mL3.5178 mL7.0356 mL
10 mM0.3518 mL1.7589 mL3.5178 mL
50 mM0.0704 mL0.3518 mL0.7036 mL

Description

KRIBB11 abolishes the heat shock-induced luciferase activity with an IC50 of 1.2 μM. It is an inhibitor of the transcription factor . KRIBB11 induces growth arrest and .

Targets

HSF1 [1]
(Cell-based assay)
1.2 μM

In vitro

KRIBB11 inhibits HSF1 activity in a concentration-dependent manner. It down-regulates HSP70 and HSP27. KRIBB11 can inhibit cancer cell proliferation, arrests the cell cycle at G2/M phase and induces apoptosis. But it does not inhibit heat shock-induced recruitment of HSF1 to the hsp70 promoter or phosphorylation of HSF1 Ser-230. KRIBB11 inhibits heat shock-induced recruitment of pTEFb to the hsp70 promoter and p-TEFb-dependent Phosphorylation of polⅡ CTD Ser-2.

In vivo

Using a mouse xenograft model, KRIBB11 treatment decreases tumor volume by 47% compared with untreated control mice. In addition, HSP70 protein levels are significantly decreased in tumors from mice treated with KRIBB11, supporting the notion that KRIBB11 exerts its in vivo antitumor activity through HSF1 inhibition.